FDA moves toward easing restrictions on certain peptides BioPharma Dive The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The peptide problem: Hype is outrunning the evidence Peptides, Drugs And Supplements: Science, Risks, And Alternatives Los Angeles Times